{"id":"NCT04167462","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-25","primaryCompletion":"2021-03-08","completion":"2022-01-07","firstPosted":"2019-11-18","resultsPosted":"2022-11-02","lastUpdate":"2023-03-08"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"BMS-986165","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A:BMS-986165 oral administration","type":"EXPERIMENTAL"},{"label":"Arm B: Placebo oral administration","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea","primaryOutcome":{"measure":"The Percentage of Participants With sPGA Response of 0 or 1","timeFrame":"At week 16","effectByArm":[{"arm":"Arm 1: BMS-986165","deltaMin":55.6,"sd":null},{"arm":"Arm 2: Placebo","deltaMin":6.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":34,"countries":["China","South Korea","Taiwan"]},"refs":{"pmids":["40671612"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":74},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Mouth ulceration","Psoriasis","Headache"]}}